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Introduction: The tricyclic indole compound, [18F]GE-180 has been previously identiﬁed as a promising positron emis-
sion tomography(PET) imagingagentof the translocatorprotein (TSPO)with thepotential to aid in thediagnosis, prog-
nosis and therapy monitoring of degenerative neuroinﬂammatory conditions such as multiple sclerosis. [18F]GE-180
was ﬁrst identiﬁed and evaluated as a racemate, but subsequent evaluations of the resolved enantiomers have
shown that the S-enantiomer has a higher afﬁnity for TSPO and an improved in vivo biodistribution performance, in
terms of higher uptake in speciﬁc brain regions and good clearance (as described previously). Here we describe the
additional biological evaluations carried out to conﬁrm the improved performance of the S-enantiomer and including
experiments which have demonstrated the stability of the chiral centre to chemical and biological factors.
Materials andMethods:GE-180 and the corresponding radiolabelling precursorwere separated into single enantiomers
using semi-preparative chiral supercritical ﬂuid chromatography (SFC). A detailed comparison of the individual enan-
tiomers and the racematewas carried out in a number of biological studies. TSPO binding afﬁnity was assessed using a
radioligand binding assay. Incubation with rat hepatic S9 fractions was used to monitor metabolic stability. In vivo
biodistribution studies up to 60min post injection (PI) in naïve rats were carried out tomonitor uptake and clearance.
Achiral and chiral in vivometabolite detectionmethodswere developed to assess the presence ofmetabolite/s in plas-
ma and brain samples, with the chiral method also determining potential racemisation at the chiral centre.
Results: Evaluation of the chiral stability of the two enantiomers to metabolism by rat S9 fractions, showed no
racemisation of enantiomers. There were notable differences in the biodistribution between the racemate and the
R- and S-enantiomers. All compounds had similar initial brain uptake between 0.99 and 1.01% injected dose (id)
at 2 min PI, with S-[18F]GE-180 showing signiﬁcantly greater retention than the R-enantiomer at 10 and 30 min
PI (P b 0.05). S-[18F]GE-180 uptake to the TSPO-expressing olfactory bulbs was 0.45% id (SD ± 0.17) at 30 min PI
in comparison to RS-[18F]GE-180 or R-[18F]GE-180 levels of 0.41% id ±0.09 and 0.23% id ±0.02 respectively, at
the same timepoint (P N 0.05). The signal-to-noise ratio (ratio olfactory bulb to striata binding) were similar for
both RS-[18F]GE-180 and S-[18F]GE-180 (3.2 and 3.4 respectively). Initial uptake to the lungs (an organ with high
TSPO expression) was more than 3-fold greater with S-[18F]GE-180 than R-[18F]GE-180, and signiﬁcantly higher
at 10 and 30 min PI (P b 0.05). Furthermore lung uptake of S-[18F]GE-180 at 2 and 10 min PI was also signiﬁcant
when compared to the racemate (P b 0.05).
Themajority of the radioactivity in the rat brain following administration of RS-[18F]GE-180 or S-[18F]GE-180 was due to
thepresenceof theparent compound (91%±1.5 and94%±2.0of total radioactivity at 60minPI respectively). In contrast
at 60min PI for the plasma samples, the parent compounds accounted for only 28%±1.2 and 21%±4.6 of total radioac-
tivity for RS-[18F]GE-180 and S-[18F]GE-180 respectively. Chiral assessment conﬁrmed that the S-enantiomer was chirally
stable in vivo, with no stereochemical conversion in brain and plasma samples up to 60min PI.
Conclusions: Developing racemic radiotracers, as for racemic therapeutics, is a considerable challenge due to dif-
ferences of the enantiomers in pharmacokinetics, efﬁcacy and potential toxicity. We have shown that the enan-
tiomers of the promising racemic PET ligand [18F]GE-180 do not share identical performance,with S-[18F]GE-180
demonstrating higher TSPO afﬁnity, higher brain uptake and better retention to the high TSPO-expressing lungs.
Furthermore, S-[18F]GE-180 has also been shown to be enantiomerically stable in vivo, with no observed conver-
sation of the eutomer to the distomer. As a single enantiomer, S-[18F]GE-180 retains the beneﬁcial characteristics
of the racemate and is a promising imaging agent for imaging neuroinﬂammation in vivo.
© 2015 Elsevier Inc. All rights reserved., The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL, UK.
ine and Biology 42 (2015) 711–7191. IntroductionTranslocator protein (TSPO) is an 18 kDa, ﬁve transmembrane do-
main protein formerly known as the peripheral benzodiazepine recep-
tor (PBR). It is primarily located within the outer membrane of the
mitochondria where it forms a part of a multimeric complex along
with the 32 kDa voltage-dependent anion channel, and the 30 kDa ade-
nine nucleotide translocase [1]. TSPO is involved in steroidogenesis,
whereby TSPO mediates cholesterol transport into mitochondria
[2–6], but the precise functions of TSPO during neuroinﬂammation are
not yet fully understood. There is however a signiﬁcant increase in
TSPO expression in immune cells (ostensibly microglia) as part of the
neuroninﬂammatory cascade that follows a cerebral insult [7].
The correlative relationship between increased TSPO expression and
neuroinﬂammation has in recent years led TSPO to be the main target
for imaging neuroinﬂammation [8]. [11C]-R-PK11195 was the ﬁrst of
the non-benzodiazepine and selective TSPO radioligands that was clin-
ically established [9] and has been used inmany clinical and pre-clinical
PET studies. Whilst [11C]-R-PK11195 has been employed inmany infor-
mative studies of immune cell activation, it is not an ideal PET imaging
tracer [10]. Therefore, in recent years there has been a desire to ﬁnd
new improved in vivo TSPO PET and single photon emission computer
tomography (SPECT) ligands with improved pharmacokinetic proper-
ties. As a result, there have been several new promising ligands that
have been identiﬁed and evaluated [11–13]. We have evaluated several
different classes of TSPO ligands, which have led to the development of
new potential TSPO tracers (includes: diaryl anilide, tetracyclic and tri-
cyclic indole classes) [14–16]. Here we will describe more extensively
the investigation and evaluations which identiﬁed S-[18F]GE-180 as a
promising TSPO imaging candidate [14].
GE-180 has a single chiral centre andwas ﬁrst synthesised and eval-
uated as a racemate (Fig. 1). GE-180 was separated into S- and R- iso-
mers, and the absolute stereochemistry of each was determined using
vibrational circular dichroism (VCD) spectroscopy [17]. Since it has
been known that enantiomers may have different pharmacokinetic,
pharmacodynamics and safety/toxicity proﬁles compared to that of its
racemate form [18,19] further experiments on the individual stereoiso-
mers were essential. In pharmacology, the activity of racemic drugs can
be divided into three main groups: 1 — Racemic drugs with one major
bioactive enantiomer, 2— racemic drugswith equally bioactive enantio-
mers or 3 — racemic drugs with chiral inversion. Often, it is the case of
one enantiomer containing all of the desired bioactivity (known as the
eutomer) with the other enantiomer, the distomer being less active
(group 1). In some extreme cases, the individual enantiomers have
markedly different and extreme effects (such as for Thalidomide
where one enantiomer is effective against nausea for pregnant women
and the other teratogenic for the unborn foetus; see [19] for review).
On the whole, a single enantiomer is preferable than its racemate
form, as to ensure the best performance as a radiotracer. In general sin-
gle enantiomer drugs reduce the potential for complex drug
712 W.-F. Chau et al. / Nuclear MedicFig. 1. The molecular structures of [18F]GE-180 (A) racemate: (RS)-N,N-diethyl-9-(2-[18F]
ﬂuoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide and its enantio-
mers (B) S-enantiomer: (S)-N,N-diethyl-9-(2-[18F]ﬂuoroethyl)-5-methoxy-2,3,4,9-
tetrahydro-1H-carbazole-4-carboxamide S-enantiomer and (C) R-enantiomer: (R)-N,N-
diethyl-9-(2-[18F]ﬂuoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide.interactions, have less complex pharmacokinetic proﬁles, less complex
relationships between plasma concentration and effect as well as a po-
tential for an improved therapeutic index [18]. Since, the chiral stability
of the active enantiomer of the related tetracyclic class of the TSPO li-
gands was previously evaluated and showed good stability during
radiosynthesis and in formulation but rapid racemisation in plasma
[16], it was crucial to demonstrate the stability of S-[18F]GE-180 (of
the tricyclic class) in biological media. Hence the individual enantiomers
of [18F]GE-180 were prepared and investigated in a series of biological
tests. The key biological considerations are essentially metabolic stability,
speciﬁc binding and ligand receptor kinetics (i.e. brain uptake and wash-
out). Fig. 2 shows the assessment approach adopted in this study.
The afﬁnities and the regional brain biodistribution data of the
racemate and both its enantiomers were published previously in brief
[14], however the exact steps andmethod have been described in further
details in this paper.2. Materials and methods
2.1. Synthesis and radiosynthesis of [18F]GE-180
Unlabelled GE-180 and the corresponding mesylate radiolabelling
precursor was prepared according to themethods previously published
[14,20] and resolved to the single enantiomers using supercritical ﬂuid
chromatography (SFC) to givematerials with N99% enantiomeric excess
(ee). [18F]GE-180 was manufactured on a FASTlab platform with [18F]
Fluoride supplied from a GE Healthcare PET cyclotron. Kryptoﬁx 222
(K2.2.2) (4mg, 10.6 μmol), potassium bicarbonate (10 μmol) and aceto-
nitrile (0.5 mL) were added to [18F]F−/H2O (ca. 400 MBq, 100–300 μL)
in a cyclic oleﬁn copolymer (COC) reaction vessel. The mixture was
dried by heating at 100 °Cunder a streamof nitrogen for 20–25minutes.
After drying and without cooling, the mesylate precursor compound (S)-
2-(4-(diethylcarbamoyl)-5-methoxy-3,4-dihydro-1H-carbazol-9(2H)-
yl)ethyl methanesulfonate (1 mg, 1.5–3 μmol) in acetonitrile (1 mL) was
added to the COC reaction vessel and heated at 100 °C for 10 minutes.
After cooling, the reaction mixture was removed and the COC reaction
vessel rinsed with water (1.5 mL) and the rinsate added to the main
crude reaction. Following this, the crude product was applied to a semi-
preparative HPLC system (Hichrom ACE 5 C18 column (5 μm,
100 × 10 mm internal diameter; 100 Å, particle size 5 μm); mobile
phase (50% water and 50% acetonitrile) were delivered at a ﬂow
rate of 3 mL/min; UV detector set to a detection wavelength of
254 nm). The [18F]GE-180 fraction was then diluted to a volume of
10 mL with water and adsorbed on a tC18 Sep-Pak (lite) cartridge
(pre-conditioned with 2 mL of ethanol followed by 5 mL of water-for
the low radio-activity preparation). The cartridge was washed with
water (2 mL), and eluted in the ﬁnal formulation with anhydrous
ethanol (0.5 mL) followed with Dulbecco's phosphate buffered saline
(PBS at 4.5 mL), physiological pH 6–9. Radioactivity was measured
using a radioisotope dose calibrator (Capintec CRC-15R).
High activity radiosysntheses were also prepared depending on the
study demand on the study day. For the higher activity radiosynthesis
preparations from a starting activity of approximately 40GBq, the
above steps were carried out but with the added steps of using ascorbic
acid as a radio-stabiliser in the following: HPLC eluent (as 0.1 mg/mL
ascorbic acid in water), 20 mL PBS containing 20 mg ascorbic acid
HPLC vial) and to pre-condition the tC18 cartridges (as a 1 mg/mL in
5 mL solution in water). The radiolabelled molecules were puriﬁed by
HPLC prior to the biological evaluations, using a Chromolith RP-18E
100 × 4.6 mm column with water and methanol on a gradient method.
Chiral HPLC analysis of the radiolabelled compoundswas carried out
to determine if any racemisation had occurred during radio-synthesis.
The effect of changing the reaction temperature on the chiral integrity
of the synthesis was also evaluated. Both reducing and increasing the
reaction temperature and heating duration were assessed. Reaction
Identification of 
primary candidates:
RS-, R- and S-
enantiomers 
(Separation of 
enantiomers by SFC)
In vitro binding in rat & human TSPO for unlabelled RS-, 
R-or S-enantiomers
In vitro incubation of unlabelled R-or S-enantiomers with 
rat S9 (metabolites assay)
Low activity 
radiosynthesis of RS, 
R- or S-enantiomers
In vivo biodistribution in naïve rat following 
administration of radio-labelled RS-, R- or S-enantiomers
In vivo metabolites quantification in naïve rat following 
administration of radio-labelled RS- or S-enantiomers
High activity 
radiosynthesis of RS-, 
R- or S-enantiomers
In vivo chiral metabolites quantification in naïve rat 
following administration of radio-labelled RS- or S-
enantiomers and assessment of racemisation in vivo
following administration of S-enantiomer
Fig. 2. Assessment approach.
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standard reaction conditions of 100 °C/15 min.
2.2. Separation of the enantiomers by SFC
The racemate was resolved into its individual enantiomers by SFC
[21]. One hundred milligrams of the RS-GE-180 crude were dissolved
with minimal volume of 1.4-dioxane, resulting in up to 40 mg/mL
stock solutions. The combined fractions from the SFC puriﬁcations had
the organic solvents removed by evaporation at 40 °C, to form a ﬁlm.
The ﬁlm was dissolved by ﬁrst adding 15 mL acetonitrile and then
30mLMilli-Q water, before the ﬂasks were frozen using dry ice and ac-
etone. After the solution was frozen both ﬂasks were freeze dried using
a Sentry 2.0 freeze dryer. Separation was carried out, by the use of a
Kromasil Amycoat 250 × 10 mm 5 μm, 100 Å column at 40 °C under
isocratic conditions (20% isopropyl alcohol over a 10 min run at a ﬂow
of 1.4 mL/min). Enantiomeric purity determination was carried out by
a chiralpak IC (cellulose tris(3,5-dichlorophenyl)carbamate based),
250 × 4.6 mm, 5 μm, column (from Chiral Technologies) under isocratic
conditions (80% water:20% methanol v/v) at 1 mL/min ﬂow rate over a
20 min run.
2.3. In vitro afﬁnity
This method involved a competition binding assay of the racemate,
R- and S-enantiomers binding to Wistar rat heart TSPO (n = 2 for all
compounds) against 0.3 nM [3H]PK11195 (reference) using an adapted
method from Le Fur et al. [22]. Reactions were carried out in 50 mM
Tris-HCL (pH 7.7) 10 mM MgCl2 and incubated in 1% DMSO at 25 °C
for 15 min, with the reaction terminated by rapid vacuum ﬁltration of
the contents onto glass ﬁbre ﬁlters. The radioactivity collected was
then compared to those of the control values in order to ascertain
any interactions of the test compounds with the TSPO binding site. In
addition, the three compounds were run against human TSPO (human
colonic cell membranes), whereby reactions were carried out at room
temperature, and in rat kidney membranes (0–4 °C) for 60 min. In gen-
eral, each non-radioactive test compound was screened at 12 different
concentrations (n = 2).
2.4. In vitro metabolites
Unlabelled S-GE-180 and R-GE-180 were spiked into plasma
samples and were incubated for up to 4 hours at 37 °C to study in vitro
chiral stability. Unlabelled S-GE-180 (~25 μL) was also incubated with
S9 rat liver fractions (~200 μL), containing tris-HCL buffer (~575 μl)
and beta-nicotinamide adenine dinucleotide phosphate, β-NADPH
(~200 μL) for up to 4 hours at 37 °C to study potential racemisation.In brief, 100 μL aliquots of the testmixture samples (duplicates) after in-
cubationwere added to ice cold acetonitrile and ethanol (left over night
in the fridge for protein precipitation), mixed and then centrifuged. The
supernatant was then subsequently evaporated to dryness by N2-gas
and then the dried extracts re-dissolved in acetonitrile (100 μL). HPLC
analysis was then performed on the processed samples, using an
online Solid Phase Extraction (SPE) cartridge (LiChrospher ADS RP-4,
25 × 4 mm, 25 μm) and then a chiral column (Chiralpak IC 0.46 × 25 cm)
using a UV/visible detector (at 230 nm). Elution was by a gradient method
using 10 mM ammonium acetate in acetonitrile and methanol over a
41 minute run with a ﬂow of 500 μL/min. The samples incubated in S9,
were also analysed on the same chromatograph equipped with a Waters
XBridgeShieldRP182.5 μm,4.6×50mmcolumn.Agradient of 10mMam-
monium acetate and acetonitrile over a gradient for 12minwas applied, at
a ﬂow of 500 μL/min.2.5. In vivo biodistribution studies
All animal experiments were carried out in compliancewith the An-
imals (Scientiﬁc Procedures) Act 1986 act, and all regulated procedures
within this study were carried out by qualiﬁed personnel. All animals
were allowed at least 3 days acclimatisation in the animal housing
unit before being included in the study.
Naïvemale Sprague Dawley rats weighing ~ 200–250 gwere admin-
isteredwith approximately 1 to 3MBq of the test compound per animal.
The tracers were injected intravenously via a tail vein in a volume of ap-
proximately 0.1 to 0.3mL. A total of 6 animalswere used at each of the 2,
10, 30 and 60 min post injection (PI) timepoints over two study days.
Sacriﬁce was by cervical dislocation while under gaseous anaesthesia
(with 4% isoﬂurane in oxygen). Immediately after sacriﬁce, the brains
were removed and dissected. Other organs, tissue and excreta were
also dissected and assayed for radioactivity using a purpose-built
gamma counter (the hardware for the counter was commissioned to
GravatomEngineering Systems and the software to Solcom; the counter
was capable of assessing whole organs and provides counts for the en-
tire animal). The decay corrected percentage of injected dose (% id)
for each sample was calculated. For blood, bone, muscle, skin and fat,
where representative sampleswere collected, appropriate body compo-
sition factors were applied for these tissue samples in order to calculate
the % id in the entire tissue. All the other tissues, organs and excreta,
were collected intact at dissection and the % id calculated as a percent-
age of the total radioactive dose administered. Activity of the regionally
dissected brain samples were measured on a Wallac gamma counter
before being combined and included as a whole brain sample on the
purpose-built gamma counter. In vivo biodistribution was carried out
for RS-[18F]GE-180, S-[18F]GE-180 and R-[18F]GE-180 (n = 2–6).
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Male Wistar rats (~200 g bodyweight) were anaesthetized using
isoﬂurane (4% isoﬂurane in oxygen). In separate studies, RS-[18F]GE-
180 and S-[18F]GE-180 was intravenously injected as a bolus via a tail
vein at a radioactive dose of approximately 20 MBq in 1 mL. The rats
were allowed to recover from the anaesthesia, and then at the point of
sacriﬁce (10, 30 or 60 min PI), the rats were further anaesthetised and
then sacriﬁced by cervical dislocation. One animal was used for the 10
and 30 min PI timepoints, whereas for the 60 min PI samples, the plas-
ma or brain tissues from two animals were combined, to ensure ade-
quate radioactivity due to the short half-life cycle. A total of three
studies containing these timepoints were carried out on three separate
study days. Blood was collected from the vena cava, transferred to a
Vacutainer (pre-coated with Ethylenediaminetetraacetic acid anticoag-
ulant), mixed, transferred to an eppendorf tube and then centrifuged at
3500 × g for 3 min to obtain plasma. The brain was removed from the
skull and the cerebellum, medulla and pons discarded. All samples
were immediately transferred on wet ice for sample clean up (protein
precipitation) prior to HPLC analysis. Although different rat strains
were used in the metabolism studies than for the biodistribution stud-
ies, both Wistar and Sprague Dawley rats are from the same main
class of outbred albino stocks. This is considered to haveminimal impact
on the validity of the study, whichwere focused on the distribution and
metabolism of GE-180 in a naïve animal expressing low (normal) levels
of TSPO.
2.6.1. Preparation of in-vivo samples for HPLC analysis
(for the achiral analysis)
Plasma samples from each of the time-points above were added to
ice cold 100% acetonitrile in a 1:10 volume per volume (v/v) ratio and
centrifuged at 132000 rpm (approximately 16000 × g) for 3 min to
allow for protein precipitation. Similarly the brain sample was homoge-
nized with ice-cold acetonitrile (10mL per brain sample) using a rotary
blade homogeniser atmaximumspeed for approximately 1min, follow-
ed by centrifugation at 5000 rpm (approximately 4500 × g) for 5 min.
For both plasma and brain samples, following centrifugation the super-
natant was removed by rotary evaporation at 40 °C, followed by recon-
stitution of the plasma pellet with 2.5 mL of mobile phase (60%
acetonitrile and 40% water). The resulting sample was then passed
through a 0.22 μm low protein binding ﬁlter to remove particulates
prior to HPLC injection. Radioactivity was assayed using a gamma coun-
ter at each stage to monitor extraction recoveries.
2.6.2. HPLC analysis by the achiral method
HPLC was used to analyse the radiochemical proﬁle of the metabo-
lites and the parent peak. A 1mL aliquot of sample (after protein precip-
itation) was manually injected into a Rheodyne injector and analysed
using a C18 semi-preparative 7.8 × 300 mm; 10 μm;125 Å μBondapak
column (Waters), with a C18 Vydac 218 TD 5 μm guard cartridge
(Grace). Analysis was carried with an isocratic method with 60% HPLC
grade water (mobile phase A) and 40% HPLC grade acetonitrile (mobile
phase B) running over a 20 min run time at a ﬂow rate of 3 mL/min
(from a binary pump). The separation was performed at ambient tem-
perature. Radioactivity detection was via a dual Bismuth Germanate
(BGO) coincident radioactive detector with a 500 μL loop and a
bioscan ﬂow count. The ultraviolet (UV) absorbance was captured
with an UV/Vis detector set at a wavelength of 230 nm with an
absorbance unit full scale (AUFS) of 0.1. A universal chromatographyProtein precipitation 
via centrifugation
Filtration us
Whatman 0
Mini Uniprep
Fig. 3. The three stages of plasma sample cinterface (UCI) was used to convert the electronic signal to digital
data. The Chromeleon HPLC software (version 6.6 Dionex) was used
for data acquisition and integration. The area under the curve of the
parent peak from the radio trace represented the radio chemical purity
(RCP). The parent peak of the tracer of interest in each study was veri-
ﬁed on the HPLC proﬁles by co-injection with the corresponding non-
radioactive compound i.e. by retention time comparison.
2.7. In-vivo metabolites (chiral analysis)
Approximately 40MBq (in 1mL) of RS-[18F]GE-180 or S-[18F]GE-180
was administered intravenously to male Wistar rats (~200 g) using the
same procedure and timepoints as mentioned previously in the achiral
methodology. Sample processing followed by HPLC analysis was then
carried out. The RS compound was analysed once on the chiral set-up
(Fig. 7 traces A, D and E) simply to show elution order of the isomers.
The R-[18F]GE-180 injection was similarly analysed only once on the
system, to further verify the approximate retention time of this isoform.
The S-enantiomer (compound of interest) was analysed in triplicate
(example chromatographs Fig. 7 traces B, F and G), to show repeatabil-
ity. Single injections of both the RS- compound and R-enantiomer were
considered sufﬁcient for the purpose of verifying that this methodology
was capable of detecting both isoforms.
2.7.1. Preparation of in vivo samples for HPLC analysis (by chiral analysis)
Similar to the achiralmethodology, all the biological samples prior to
HPLC analysis were processed to remove proteins and phospholipids
from the sample matrix. This is especially important with the use of a
chiral column, due to its sensitivity to overloading affecting column
usage. The protein precipitation for the brain samples for chiral analysis
was carried out in the same way as described for the samples subjected
to achiral analysis above, with the exception that themobile phase used
for re-constitution was 85% methanol and acetonitrile (50/50 v/v) and
15% 10 mM ammonium acetate.
However for plasma samples three stages of sample processingwere
carried out (Fig. 3). A mixture of ice-cold methanol and acetonitrile
(50%:50% v/v) was used as the extraction solvent with a 1:10 v/v
ratio of plasma to solvent being used and centrifuged at 132000 rpm
(approximately 16000 × g) for 3 min to allow for protein precipitation.
After protein precipitation 0.4 mL of the reconstituted sample was
ﬁltered through a Mini Uniprep system (GE Healthcare Whatman) to
further eliminate particulate matter. The ﬁltrate was then placed onto
the auto sampler for injection on to the ﬁnal online SPE clean up
stage. Similarly for the achiral method, aliquots were measured for
radioactivity on the gamma counter at each stage to account for extrac-
tion recoveries.
2.7.2. HPLC analysis by the chiral method
A chiral HPLC method was developed and optimised to primarily
assess potential racemisation of S-[18F]GE-180 in vivo. In addition, RS-
[18F]GE-180 was also analysed to demonstrate that the methodology
was capable of detecting both forms of enantiomers. The method
consisted of an online solid SPE clean up (the ﬁnal clean up stage after
ﬁltration using the mini uni-prep system), followed by a chiral separa-
tion method. The same radio- and UV-detection set-up was used as
with that of the achiral method but with a smaller sample loop of
200 μL in the BGO detector. A 16min gradient run programmewas per-
formed at a ﬂow rate of 1 mL/min (Table 1) using degassed and ﬁltered
buffers (mobile phase A = 10 mM ammonium acetate and B = 50%ing the 
.45µm 
 system
Online C4 SPE 
lean up prior to chiral HPLC analysis.
Table 1
SPE (pump 1) and chiral column gradient programme (pump 2) with valve set up state.
Time (min) Pump 1 Pump 2 Valve state Description
% Mobile phase A % Mobile phase B % Mobile phase A % Mobile phase B
0 90 10 60 40 Load SPE load stage; chiral column equilibration
2 90 10 60 40 Inject SPE back ﬂushed on to chiral column
2.5 15 85 15 85 N/A N/A
5.5 15 85 15 85 Load SPE re-conditioning; sample separation on chiral column
6.1 90 10 N/A N/A N/A N/A
9.0 90 10 N/A N/A N/A N/A
9.5 0 100 N/A N/A N/A N/A
13.0 0 100 N/A N/A N/A N/A
13.5 90 10 5 95 N/A N/A
14.2 N/A N/A 0 100 N/A N/A
16.0 90 10 60 40 N/A N/A
N/A = not applicable.
715W.-F. Chau et al. / Nuclear Medicine and Biology 42 (2015) 711–719acetonitrile and 50%methanol v/v) from two binary pumps. A switching
valve was used to operate the ﬂow direction of the eluents from both
pumps at various stages. Three stages to the SPE process were carried
out with the use of a pre-programmed switching valve. The ﬁrst stage
involved the loading of the processed sample (50 μL through a 50 μL
polyether ether ketone (PEEK) sample loop by the use of an auto-
sampler) onto the C4 SPE cartridge (LiChrospher RP-4 ADS; 25 μm;
4 mm × 25 mm, 60 Å, pH range 2–7), to concentrate and to retain the
analytes of interest. The C4 cartridge allows for the retainment of the
more hydrophobic species i.e. the parent peak. The next stage, involved
the back-ﬂushing of the previously retained analytes of interest
from the SPE onto the connecting chiral column (Chiralpak IC 5 μm;
4.60 × 250 mm, Daicel) attached to a pre-guard cartridge (Chiralpak
IC 5 μm; 4.0 × 10 mm, Daicel). The ﬁnal stage, involved the separation
of the compound of interest and its metabolites on the chiral column
and SPE re-equilibration, ready for the subsequent injection.
In general, the hydrophilic analytes of interest were captured on the
hydrophobic bonded phase of the sorbent in the SPE cartridge using low
organic levels (pump 1). After sample loading onto the SPE, the direc-
tion of the ﬂow was changed, with the valve state switched to ‘inject’.
The organic phase (mobile phase B) was then increased to a high level
and remained constant at this level for a fewminutes to allow for sufﬁ-
cient back ﬂushing of the retained analytes from the SPE onto the
connecting chiral column. In parallel during the SPE loading stage, the
chiral column undergoes equilibration (operated by pump 2). After
the analytes have transferred onto the analytical column, the valve
was switched back to its original ‘load’ position, and the analyteSPE
Sample Loop
Pump 1
Auto-sampler
Pump 2
To waste
Chiral column
2
3
6
1
5
4
A
Fig. 4. Schematic of a Rheodyne valve showing the mobile phase ﬂow direction from two pump
pump l via valve at port 6 and port 1, with non-retainedmaterial beingwashed through to port
and then to waste (dashed line). b) Inject state (60 degree rotation of 6-port valve): In this pos
analytes from the SPE to port 1, then 2 and ﬁnally onto the chiral column and injection onto
Simultaneously, pump 2 ﬂushes mobile phase B to waste via port 3 and 4 (dashed line).separation was carried out over a gradient (with pump 2 pumping mo-
bile phase onto the analytical column). Meanwhile, pump 1 underwent
its own cycle of clean up and re-equilibration. A summary of both gradi-
ents used and the synchronisation of the two pumps are described in
Table 1 with a schematic of the mobile phase ﬂow direction illustrated
in Fig. 4. Recoveries were veriﬁed at each stage and were deemed sufﬁ-
cient (N70% recovery).
2.8. Statistical analysis
Where appropriate, data are presented as mean ± standard devia-
tion (SD). Two way analysis of variance (ANOVA) was used to compare
the in vivo biodistribution of the three compounds across the timepoints
in the individual organs and tissues. Where ANOVA indicated a signiﬁ-
cant difference, a post hoc Student t-test (unpaired; Prism) compared
the groups, and statistical signiﬁcance was considered where P b 0.05.
3. Results and discussion
3.1. Radiochemistry
For the lower-activity radiosyntheses of S-[18F]GE-180 the radio-
chemical yield was 26% (based on n = 8) non-decay corrected with a
process time of 90 minutes, and the radiochemical purity (RCP) was
N99% in all preparations. For the higher-activity radiosyntheses (for S-
[18F]GE-180) the end of synthesis yields were typically 7 to 12%
(non-decay corrected based on n = 2). Before biological evaluation,Pump 1
Auto-sampler
SPE
Pump 2
To waste
1
2
3
Sample Loop
6
4Chiral column
B
5
s to the SPE cartridge and to the chiral column. a) Load state: Sample loading onto SPE by
5, 4 and then towaste (solid line); Chiral column equilibration by pump 2 via port 3, port 2
ition, the ﬂowwas reversed from port 5 with eluent back ﬂushing the previously retained
the connecting chiral column followed by separation operated by pump 1 (solid line).
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A higher radioactivity was required for the chiral metabolism method, to
compensate for the less volume per concentration injected onto the HPLC
and the overall longer sample processing time required. SigniﬁcantFig. 5. Biodistribution data comparing % radioactivity in key organs and tissues after administrati
(n= 3–6; 10–22 GBq/μmol) or R-[18F]GE-180 (n=2–3; 83 GBq/μmol) in naïve Sprague Dawleydegradation to the mesylate precursor to the corresponding alcohol and
vinyl impurities was observed as a result of heating, as expected with the
higher temperature/longer time duration (130 °C/30 min) compared to
the lower temperature and shorter time duration setting (80 °C/15 min).on of 1-3 MBq of RS-[18F]GE-180 (n = 3–6; speciﬁc activity 4–21 Gbq/μmol). S-[18F]GE-180
rats at 2, 10, 30 and 60min PI. Error bars= standard deviation. HBS= hepatobiliary system.
Fig. 6. Biodistribution of S-[18F]GE-180 in A) key brain regions B) other organs in Sprague Dawley rats at 2, 10, 30 and 60 min PI (n = 3–6). For further details see Fig. 5 legend.
717W.-F. Chau et al. / Nuclear Medicine and Biology 42 (2015) 711–719End of synthesis yield of 20% and 11%were obtained respectively, with 99%
ee and N99% radiochemical purities obtained on all accounts.
3.2. In vitro afﬁnity
In rat heart, S-GE-180 was found to be more potent, with an Ki of
0.87 nM, ~4.4 fold higher than the less active R-GE-180 enantiomer
with a Ki of 3.87 nM as previously reported [14]. The afﬁnity for S-GE-
180 correlated well with RS-GE-180 (Ki 0.59 nM). In human, the results
were similar in terms of potency order with S-GE-180 (9.2 nM) being
the most potent, followed by RS-GE-180 (11.5 nM) and then S-GE-
180 (14.1 nM).
3.3. In vitro metabolites
Racemisation of the test compound in plasma would be inferred by
the presence of the opposite enantiomer. Following chiral HLPC analy-
sis, only the parent peak was observed for each of the test compounds,
demonstrating stability of the enantiomers in plasma. Racemisation of
themore active S-GE-180 enantiomer was also not observed after incu-
bation with the rat S9 liver fraction i.e. the S-GE-180 enantiomer does
not racemise to R-GE-180. Low levels of unidentiﬁed polar metabolites
(7%) were observed after 4 hours incubation in both enantiomers.
3.4. In vivo biodistribution
Following intravenous administration, S-[18F]GE-180 displayed the
most rapid radioactivity clearance from blood at early timepoints,
followed by the racemate and then R-[18F]GE-180 (Fig. 5A). A steady-
state level (~0.1% id/g) by 30 min was reached for all three test com-
pounds, except for R-[18F]GE-180, which increased to 0.2% id/g levelsTable 2
Mean total relative percentage of parents andmetabolites ± standard deviation (by achiral HPL
sacriﬁced at 10, 30 & 60 min PI (n = 3).
Sample Species RS-[18F]GE-180 Mean total relative % ± SD
10 min PI 30 min PI
Brain Parent 100 97 ± 1.0
Metabolites 0 3 ± 1.0
Plasma Parent 81 ± 3.5 49 ± 12.5
Metabolites 19 ± 3.5 51 ± 12.5
Speciﬁc activity was between 3 and 82 GBq/μmol.at 60 min PI. In general there was lower uptake in the plasma samples
at the initial timepoint compared to blood, which similarly reached a
steady state level of approximately 0.1% id/g by 30 min (for all three
compounds) (Fig. 5B). Brain uptake of N0.5% id/g by 2min for TSPO cen-
tral nervous system (CNS) tracers is considered desirable [23]. Although
this uptake was exceeded by all three compounds, with similar whole
brain uptake of between 0.99 and 1.01% id (equivalent to 0.51 to 0.53
id/g) at 2 min PI (Fig. 5C), the retention of S-[18F]GE-180 was signiﬁ-
cantly greater than R-[18F]GE-180 by 10 min PI, with activity levels re-
maining higher for as long as 30 min PI (P b 0.05). The washout (rate
of initial brain uptake at 2 min compared to brain uptake in subsequent
timepoints) was fast for all three compounds with no signiﬁcant differ-
ence (P N 0.05; Fig. 5C). The ability to penetrate the blood brain barrier
(BBB) and have fast washout kinetics are highly desirable properties for
a useful brain imaging agent; a criteria met by all the [18F]GE-180 com-
pounds. The difference in tracer retention between the high TSPO ex-
pressing olfactory bulbs and the low expressing striata have been used
as the basis for determining speciﬁc signal uptake to non-speciﬁc clear-
ance of potential TSPO binding imaging agents, as previously described
[14]. The more active S-[18F]GE-180 demonstrated OB retention at
30 min PI of 0.45% id compared to RS-[18F]GE-180 of 0.41% id and R-
[18F]GE-180 of 0.23% id (P N 0.05). Clearance from the non-selective re-
gions (striata) was rapid and reached a steady state by approximately
30 min PI (Fig. 5D), with all three compounds showing similar clear-
ance. The olfactory bulb/striata ratios (indicative of speciﬁc to non-
speciﬁc binding) were also similar and in the order of S-[18F]GE-180
(3.2), RS-[18F]GE-180 (3.4) and R-[18F]GE-180 (2.9). The organ with
the highest initial uptake at 2 min was to the lungs (example Fig. 6A);
this was consistent with other selective TSPO ligands, as is the subse-
quent rapid clearance in this organ by 30 min PI in all three test com-
pounds (Fig. 5E) (P b 0.05 for S-[18F]GE-180 versus R-[18F]GE-180 atC analysis) inWistar rats after administration of RS-[18F]GE-180/S-[18F]GE-180 (~20 MBq)
S-[18F]GE-180 Mean total relative % ± SD
60 min PI 10 min PI 30 min PI 60 min PI
91 ± 1.5 98 ± 1.7 96 ± 2.6 94 ± 2.0
9 ± 1.5 2 ± 1.7 4 ± 2.6 6 ± 2.1
28 ± 1.2 70 ± 18.2 41 ± 16.2 21 ± 4.6
72 ± 1.2 30 ± 18.1 59 ± 16.4 79 ± 4.6
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Fig. 7. Example radio-HPLC chromatograms showing the elution order of the S-enantiomer followed by the R-enantiomer in both in vivo samples (traces E, F & G) and spiked (ex vivo)
samples (traces A,B & C), with a metabolite species obtained in the 60 min in vivo plasma and brain samples. The HPLC chromatographs show a response of millivolts (mV) on the y
axis and time (min) on the x axis. The numbers displayed on the top of each peak shows the peak numbering followed by the retention time. Chromatogramswere not decayed corrected,
but samples were injected onto the HPLC as soon as possible in each instance. In this study, spiked sample refers to mobile phase spiked with the radiolabelled compound of interest).
Where applicable, the S-, R- and metabolite peaks are represented by a solid, dash and square dot arrows respectively. The retention times of the metabolite, S- and R- peaks were con-
sistently ~8.8, ~9.8 & ~10.5 min respectively. The reduced signal/noise ratio observed in the 60 min plasma samples (Fig. 7 D and F) was as expected due to the limited amount of radio-
activity injected onto theHPLC as a result of the extra sample processing stage used. One hydrophilic non-parent peakwas observed in the 60min plasma and brain samples following RS-
compound injection (Fig. 7D), since the run time of this peak was different to that of the S-enantiomer (Fig. 7B), this was conﬁrmed to be the metabolite and not the parent peak.
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and 10 min PI). Excretion for all test compounds was primarily via the
hepatobiliary system (HBS), with activity contained within the liver, in-
testines and faeces. Urinary excretion accounted for a smaller % id than
HBS, irrespective of the timepoint (Fig. 5F). In brief, the biodistribution
data show the single S-enantiomer, S-[18F]GE-180 to have comparable
properties to the racemate and supports the single S-enantiomer as
the lead candidate.
The highest TSPO expressing region in the rat brain are the olfactory
bulbs, with one of the lowest expressing regions being the striatium
(Fig. 6A). The general distribution (Fig. 6B) shows the lung displaying
the greatest uptake compared to the other organs at the earlier timepoints
of 2 and 10min PI only (e.g. muscle, kidneys, liver, heart, skin and fat). In
addition, bone activity levels also increased slightly with time from 3.66%
id to 6.49% id at 2 and 60 min PI respectively for S-[18F]GE-180 (not
shown). Due to the expressions of TSPO on haematogenous cells, this is
likely to be due to selective retention to the bone marrow as opposed to
the accumulation of free radiolabelled ﬂuoride [24].Table 3
The average % activity of R- and S-enantiomers ormetabolites at 10, 30 and60 min PI in brain an
HPLC (n = 3).
% Composition after S-[18F]GE-180 Plasma
10 min PI 30 min PI
% total metabolites 16 ± 7.1 35 ± 9.7
% S-[18F]GE-180 84 ± 7.1 65 ± 9.7
% R-[18F]GE-180 0 0
Speciﬁc activity was between 33 and 588 GBq/μmol.3.5. Achiral in vivo metabolites
The in vivometabolic proﬁle of both RS-[18F]GE-180 and S-[18F]GE-
180 was assessed in brain and plasma using non-chiral reverse phase
radio-HPLC. For an imaging agent targeted at the CNS it is important
that the signal in the brain is attributable to the parent molecule and
not to radiolabeled metabolite/s. In the S-[18F]GE-180 brain sample,
there was only minimal presence of metabolite species, with 98 ± 1.7%
and 94 ± 2.0% parent detected at 10 and 60 min PI respectively. In the
plasma, the amount of radioactivity attributable to S-[18F]GE-180 was
70 ± 18.2% and 21 ± 4.6% of the total activity at the same timepoints
(Table 2). Similar results were observed following the administration
of RS-[18F]GE-180 (Table 2). Across the timepoints evaluated for S-[18F]
GE-180, only three metabolites were observed in the brain samples, all
of which were more hydrophilic than the parent compound, with the
most hydrophilic metabolite species typically being themost prominent
(not shown). The three hydrophilic metabolite species identiﬁed in the
brain (at very low proportions) were likely to be those identiﬁed in thed plasma ofWistar rats injectedwith only S-[18F]GE-180 (~40 MBq) and analysed by chiral
Brain
60 min PI 10 min PI 30 min PI 60 min PI
37 ± 4.2 0 0 0.7 ± 1.2
63 ± 4.2 100 100 99 ± 1.2
0 0 0 0
719W.-F. Chau et al. / Nuclear Medicine and Biology 42 (2015) 711–719plasma (based on similar HPLC run times). There was no novel metabo-
lite in the brain that was not observed at higher respective levels in the
plasma, suggesting that the brain metabolites are formed in the periph-
ery and have poor BBB permeability.
At the earliest timepoint (10min) there was little evidence of signif-
icant amounts of metabolites in the brain (no metabolites were detect-
ed for the racemate and nomore than 2% in total for the S-enantiomer).
Thirty minutes PI in the rat is the most relevant time point that would
equate to the expected human imaging time [25]. At that time in the
rat, there is very low proportion of metabolites detected in the brain
(3–4% of the radioactivity) for the racemate and S-enantiomer respec-
tively. This equates to an extremely low amount of material (~0.01%
total % id) due to 3–4% total relative radioactivity associated with me-
tabolites in 0.30 and 0.36% of injected dose in the rat brain at that
time for RS-[18F]GE-180/S-[18F]GE-180 respectively. For the S-
enantiomer at 60 min, only a total of 0.01% of injected dose (6% of
0.22% id) is present as metabolites in the brain (due to the low amount
of total activity in the brain at this timepoint; see Fig. 5C). The fact that
there was a slightly higher proportion of metabolites in the brain at this
later time point (6% at the ﬁnal timepoint as compared to 2% at the ini-
tial time point) suggests that themetabolite(s)may be capable of cross-
ing the BBB, and this process is slower than for S-enantiomer itself.
However the low levels of the metabolites in the plasma at the early
time point (10 min PI) and the slower transport across the BBB is indic-
ative that metabolites are not likely to impact brain uptake or retention
to such an extent as to result in poorer imaging qualities. Table 2 shows
the total relative percentage of parents and metabolites determined by
achiral HPLC.
3.6. Chiral in vivo metabolites
RS-[18F]GE-180 or S-[18F]GE-180 were intravenously administered
into male Wistar rats, with brain and plasma samples at 10, 30 and
60 min PI assessed by chiral reverse phase chromatography, for the
presence of the R-enantiomer. Peaks corresponding to both S-[18F]GE-
180 and R-[18F]GE-180 (based on retention times) were present after
injection of RS-[18F]GE-180, verifying that the method was capable of
detecting both stereoisomers (Fig. 7 trace E). The R-[18F]GE-180 peak
was not detected after injection of S-[18F]GE-180, indicating that
racemisation did not take place in vivo (Fig. 7 trace G). Peaks that
were not associated with the retention times of either the R- or/and S-
enantiomers were attributed to metabolites (Table 3). Representative
analytical radiochromatograms comparing the RS-, S- and R-
enantiomers by chiral HPLC analysis are shown in Fig. 7 trace A–G. In
general the brain samples from the chiral in vivomethod were compa-
rable to that of achiralHPLC analysiswith noorminimalmetabolites ob-
served throughout the 60 min timepoint duration.
4. Conclusions
The development of racemic compounds for radiolabelled diagnostic
tracers or therapeutic drugs is extremely challenging due to the likeli-
hood of differences between the individual enantiomers (as exempliﬁed
by the extreme and catastrophic differences in the pharmacology of the
eutomer and distomer of thalidomide). As well as differences in toxico-
logical proﬁle, enantiomers can also have disparity in pharmacokinetics
and target afﬁnity. For radiolabelled PET tracers this would complicate
the image processing required, with any algorithm having to model
for the in vivo behaviour of the radioactivity associatedwith 2 different-
ly behaving compounds. Furthermore, due to the lessons learned from
experienceswith drugs like thalidomide, the pathway for regulatory ap-
proval of racemates is considerably more difﬁcult than single enantio-
meric compounds. [18F]GE-180, a promising radiolabelled agent for
TSPO imaging by PET, is a chiral compound with two enantiomers.This study has demonstrated that these enantiomers do not share iden-
tical performance. The S-[18F]GE-180 has an afﬁnity for TSPO that is 1.5-
to 4-fold better than the R-enantiomer in rat heart and has both higher
brain uptake and greater retention to the high TSPO-expressing lungs
when injected iv to rats. Furthermore, S-[18F]GE-180 has also been
shown to be enantiomerically stable in vivo, with no observed conversa-
tion of the eutomer to the distomer. As a single enantiomer, S-[18F]GE-
180 retains the beneﬁcial characteristics of the racemate and is a prom-
ising imaging agent for imaging neuroinﬂammation in vivo.References
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